Aviado · Research
Longevity Daily
Tuesday, May 12, 2026
Listen
Today's Brief
Today's digest leads with a striking finding: just four weeks of targeted dietary changes measurably reduced biological age in adults aged 65–75, one of the clearest actionable signals from aging science this year. We also interrogate the widening gap between NAD+ marketing claims and what human trials actually show, and examine a new study that challenges the assumption that omega-3s uniformly protect the brain after injury. Rounding out the issue: a landmark Nature Reviews Genetics paper on the evolutionary roots of aging, fresh insight into metformin's gut-first mechanism, and updates on the FDA's review of both lecanemab and supplement regulations.
10 stories2 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Omega-3s After Brain Injury May Promote Tau Buildup — Not Prevent It
New research covered by Women's Health challenges the blanket assumption that omega-3 fatty acids protect the brain after injury: EPA, one of the two primary omega-3s, may actually promote accumulation of tau protein — a hallmark of Alzheimer's disease — following traumatic brain injury. The study authors concluded that omega-3s do not offer uniform neuroprotection after TBI, with effects varying significantly by fatty acid type and context. This doesn't overturn the broader evidence for omega-3 benefits, but it's an important nuance for anyone managing brain health after head trauma.
Read more →Supplements & Compounds
NAD+ Supplements Are Everywhere — But the Science Hasn't Kept Up With the Marketing
An NPR investigation finds that enthusiasm for NAD+ supplements, injectables, and IV infusions has far outpaced the available human clinical trial evidence. Scientists studying the compound say they're in an unusual position: consumer demand has exploded based on early preclinical data, before rigorous large-scale trials are complete. If you're spending on NAD+ products, the current evidence warrants caution — the potential is real, but the marketing has gotten far ahead of the proof.
Read more →Research & Papers
Nature Reviews Maps the Evolutionary Roots of Aging — and Why They Matter for Longevity
A landmark review in Nature Reviews Genetics synthesizes why aging evolves: natural selection weakens after reproductive age, allowing harmful late-acting mutations to accumulate — the so-called "selection shadow." The review explains why age-related diseases like cancer and cardiometabolic dysfunction share overlapping genetic architectures, and how modern comparative genomics and multi-omics biomarkers are now being used to rigorously test these evolutionary predictions. For health-conscious readers, the core takeaway is that aging has a unified evolutionary logic — and the most promising interventions increasingly target it at that level.
Read more →Aviado Research: Featured Longevity Analysis
Aviado Research's latest featured analysis examines emerging findings relevant to longevity and healthspan optimization. The piece provides evidence-based context for health-conscious readers navigating a rapidly evolving research landscape.
Read the full Aviado analysis →Metformin May Act Through the Gut — Not the Liver — Rewriting Decades of Assumptions
New research suggests metformin — among the most widely discussed longevity-adjacent drugs — achieves its primary metabolic effects by acting on gut tissue rather than the liver, where it was long assumed to work. This mechanistic shift matters because it reframes questions about optimal dosing, timing of administration, and which patients are most likely to benefit. The finding may also help explain the significant individual variability in how people respond to metformin treatment.
Read more →A "Digital Aging Twin" Reveals That Your Organs Age at Vastly Different Rates
Researchers from China's Aging Biomarker Consortium have built a computational framework — the "Digital Aging Twin" — that tracks how individual organs age at different speeds across adulthood and generates personalized biological age predictions. Unlike single-number composite clocks, this tool reveals that your liver might be aging faster than your heart, or vice versa, opening the door to organ-specific intervention strategies. The framework is early-stage, but if validated at scale it could enable precision healthspan approaches tailored to each person's biological weak points.
Read more →Lifestyle & Nutrition
Four Weeks of Targeted Eating Measurably Reversed Biological Age in Older Adults
Researchers publishing in Aging Cell found that adults aged 65–75 who followed a structured dietary intervention for just four weeks showed measurable reductions in biological age based on their biomarker profiles. The brevity of the effect is what makes this striking: aging biomarkers shifted meaningfully in under a month, suggesting targeted nutrition can produce detectable biological change faster than previously appreciated. This is the kind of short, actionable intervention that warrants close attention from anyone interested in reversing — not just slowing — the biological clock. As with any biomarker-based study, longer follow-up data will be needed to confirm these changes translate to lasting health outcomes.
Read more →Industry & Policy
FDA Extends Review of Subcutaneous Lecanemab, Delaying Easier Access for Alzheimer's Patients
The FDA has extended its review of a supplemental application for subcutaneous lecanemab — a potential at-home injectable version of the approved Alzheimer's drug currently administered via IV infusion in clinical settings. Subcutaneous delivery would dramatically lower the access barrier for early Alzheimer's patients, eliminating the need for regular clinic visits. The delay means patients and families waiting for this simpler option will see the timeline pushed back further.
Read more →FDA Opens Public Debate on Modernizing the Definition of "Dietary Supplement"
The FDA held a public meeting to reconsider how "dietary substance" is defined — the foundational question determining what qualifies as a supplement under a regulatory framework that has remained largely unchanged since 1994. Agency officials acknowledged the industry has grown dramatically in scale, complexity, and technological sophistication, and that current rules may no longer be fit for purpose. For consumers and supplement brands alike, new definitions could reshape which ingredients are permissible and how products must be validated before reaching store shelves.
Read more →Two National Trials Are Testing Longevity Drugs in Dogs — and the Results Could Inform Human Medicine
Two national clinical trials of anti-aging drugs, including rapamycin, are currently underway in dogs, The Washington Post reports. Dogs are increasingly valued as aging models because they share human environments, develop similar age-related conditions, and have shorter lifespans that make trials feasible on a meaningful timeline. Positive results won't automatically translate to humans, but canine trials could generate critical safety and efficacy data in a larger mammal — an important step before broader human longevity applications.
Read more →